Two techniques, one goal: preserving the hip joint

If microfracture already stimulates the hip joint to repair itself, why go further? The short answer is that what the repair tissue becomes — and how long it holds — depends on more than puncturing bone.

Both microfracture and AMIC (Autologous Matrix-Induced Chondrogenesis) are marrow stimulation procedures performed arthroscopically at the hip. Each works by drilling small holes into the subchondral bone, releasing bone marrow cells and growth factors into a cartilage defect to form what researchers call a 'super-clot' — the raw material for new tissue.

AMIC adds one step: a bi-layer collagen I/III membrane, fixed over the defect immediately after microfracture is complete. That membrane stabilises the clot inside the lesion rather than letting it disperse into the joint, and provides a scaffold that guides the body's own mesenchymal stem cells toward genuine cartilage repair rather than scar-like fibrous tissue.

The clinical question — whether that single addition translates into measurably better outcomes at the hip — is what the evidence explored below addresses.

Why hip cartilage cannot repair itself

Cartilage is unusual tissue. Unlike muscle, bone, or skin, it contains no blood vessels — and because repair cells travel through the bloodstream, an injury to hyaline cartilage cannot trigger the healing cascade that mends a torn muscle or a fractured femur. The hip's articular surface, lining both the femoral head and the acetabulum, is therefore essentially permanent: once lost, it does not grow back.

Focal defects in this surface arise through several routes. Femoroacetabular impingement (FAI) creates repetitive mechanical contact between the femoral neck and the rim of the acetabulum, shearing small areas of cartilage away. Direct trauma can produce a sudden full-thickness lesion. Early degenerative change causes progressive thinning across a localised zone before diffuse joint disease sets in. What these causes share is that the resulting void stays open — cartilage cannot fill it, and joint fluid cannot substitute for the load-bearing tissue that has gone.

Left alone, focal defects tend to enlarge as the exposed subchondral bone absorbs forces the cartilage no longer distributes, accelerating the march toward hip osteoarthritis. Hip cartilage repair — whether by marrow stimulation, scaffold augmentation, or grafting — exists to interrupt that progression. The goal is not experimental: it is durable pain relief and function sufficient to delay or avoid hip replacement altogether.

Where microfracture runs out of durability

The numbers that explain microfracture's current decline are precise enough to be useful. Kreuz et al. tracked patients after marrow stimulation and identified a clear inflection point: clinical outcome scores fell significantly between 18 and 36 months post-operatively — not as a gradual fade but as a measurable step change. Solheim et al. quantified the endpoint: survivorship dropped below 60% at three years, with a mean time to failure of approximately four years.

The tissue biology explains why. When microfracture perforates the subchondral bone plate, the super-clot that forms regenerates as fibrocartilage — a weaker stand-in for the hyaline cartilage lost. Hyaline cartilage is dense, organised, and built to distribute the cyclic loads that pass through a hip joint with every step. Fibrocartilage is softer, less well ordered, and degrades under that same loading. The repair works initially — patients typically report genuine improvement in the first year — but the tissue begins to break down before the four-year mark in a substantial proportion of cases.

There is a second, less-discussed consequence. The act of perforating the subchondral bone plate can disturb the structural layer that underpins cartilage. When that layer is altered — through subchondral sclerosis or cyst formation — the options for any subsequent cartilage repair procedure narrow. A patient whose microfracture has failed is not always a straightforward candidate for a second intervention.

Microfracture remains part of cartilage repair history, and its role in small, acute defects is well documented. The concern is not with what it achieves early, but with what tends to happen between years one and four.

How AMIC targets both failure points

Introduced by Behrens et al., AMIC (Autologous Matrix-Induced Chondrogenesis) was designed with those two failure modes in mind. The procedure begins with standard microfracture — the subchondral perforations are made in the same way, releasing the same marrow-derived stem cells and growth factors. What happens next is what changes the repair environment entirely.

Once the super-clot has formed, the surgeon places a bi-layer collagen Type I/III membrane across the defect and secures it in position. This scaffold tackles the first problem directly: instead of the clot dispersing into the surrounding joint fluid and losing biological potency, it is held within the boundaries of the defect. Think of the membrane as a container — the repair material is kept precisely where the damage is, rather than washing away.

The second function addresses tissue quality. Contained within the structured scaffold, the mesenchymal stem cells receive a more organised microenvironment. Rather than defaulting to fibroblastic scar — the path that leads to fibrocartilage — they are guided toward chondrogenic differentiation, producing repair tissue that is better organised and more mechanically appropriate than microfracture alone tends to generate. The scaffold does not guarantee hyaline cartilage, but it shifts the biological conditions in that direction.

For patients, a practical advantage is that AMIC is single-stage: both the microfracture and the membrane placement are completed arthroscopically in one procedure. This distinguishes it from two-stage options such as ACI or MACI, where a biopsy, a cell-culture period, and a second operative step are required.

What the clinical evidence shows — and where it is thin

Short-term data tell only part of the story. Head-to-head comparison of AMIC against standalone microfracture shows statistically similar improvements in the Modified Cincinnati score at both one and two years post-operatively — a finding that is expected rather than disappointing, since the marrow stimulation step is identical in both procedures. The scaffold does not accelerate early repair; it is designed to make it last longer.

That durability signal begins to emerge in the longer datasets. Schiavoni Panni et al. followed 21 patients with full-thickness defects larger than 2 cm² out to seven years after AMIC and reported sustained effectiveness — placing outcomes well beyond the 18-to-36-month deterioration window documented for microfracture alone. The Gille et al. AMIC Registry, drawing on 57 patients with a mean age of 37.3 years and a mean defect size of 3.4 cm², found statistically significant reductions in VAS pain scores at both one- and two-year follow-up (p<0.001). MRI evaluation in these cases confirmed tissue filling within the defect in most patients, though a proportion showed hypertrophy or subchondral bone changes — complications that warrant monitoring. A 2017 systematic review characterised the overall AMIC evidence base as showing tentative short-to-medium-term benefit, which reflected the maturity of the evidence at that point rather than a negative verdict on the technique.

Where the evidence is genuinely thin is in hip-specific long-term data. Most of the durability research comes from studies that included other joints alongside the hip — chiefly the knee — rather than hip-only cohorts. Hip arthroscopy datasets are structurally smaller than their knee equivalents. The mechanistic case for AMIC applies equally to the hip: clot instability and fibrocartilage default are not joint-specific problems. Even so, patients considering AMIC for a hip cartilage defect should know that long-term evidence beyond five years in hip-only populations is still accumulating.

Who is suitable and what the decision looks like in practice

Decision-making for AMIC at the hip comes down to three interconnected variables: defect size, patient age and activity demands, and procedural history.

Defect size is the primary filter. AMIC is most appropriate for focal, full-thickness hip cartilage lesions — typically those larger than 2 cm², where the durability limitations of standalone microfracture are most clinically significant. Both the Gille Registry (mean defect 3.4 cm²) and Schiavoni Panni's seven-year cohort sat squarely in this size range, providing the strongest evidence base for the technique.

Younger, more active patients have the most to gain from a procedure designed for durability. Someone in their late thirties with occupational or sporting demands faces decades of hip loading ahead; the marginal short-term equivalence between AMIC and microfracture matters far less to them than what the repair tissue does between years three and seven.

Prior procedures complicate rather than foreclose the options. Where a previous microfracture has caused measurable subchondral bone damage, repeat marrow stimulation becomes less attractive — ACI-family or osteochondral approaches may be more appropriate in that setting, and a detailed MRI review is needed before any route is confirmed.

AMIC, like all cartilage repair, is a focal defect strategy. Patients with advanced or diffuse hip osteoarthritis are not candidates for cartilage restoration; that conversation moves toward hip replacement, which is a different clinical pathway entirely.

For patients currently weighing these options, Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with clinics in Sleaford and Grantham. The decision ultimately rests on matching each individual's defect characteristics, age, and surgical history to the technique most likely to hold — which is what a structured hip consultation is designed to establish.

1. [1] Microfracture surgery. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994
2. [2] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
3. [3] Autologous matrix-induced chondrogenesis. https://en.wikipedia.org/?curid=29760859 https://en.wikipedia.org/?curid=29760859